Details for New Drug Application (NDA): 208056
✉ Email this page to a colleague
The generic ingredient in DEXILANT SOLUTAB is dexlansoprazole. There are seventeen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.
Summary for 208056
Tradename: | DEXILANT SOLUTAB |
Applicant: | Takeda Pharms Usa |
Ingredient: | dexlansoprazole |
Patents: | 6 |
Medical Subject Heading (MeSH) Categories for 208056
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | Strength | 30MG | ||||
Approval Date: | Jan 26, 2016 | TE: | RLD: | Yes | |||||
Patent: | 8,461,187*PED | Patent Expiration: | Jul 17, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Patent: | 8,784,885*PED | Patent Expiration: | Apr 15, 2024 | Product Flag? | Substance Flag? | Delist Request? | |||
Patent: | 8,871,273*PED | Patent Expiration: | Jul 11, 2028 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 208056
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | 8,784,885*PED | ⤷ Subscribe |
Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | 6,939,971*PED | ⤷ Subscribe |
Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | 7,875,292*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription